Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO). Acquired AT deficiency during ECMO is common, but formal recommendations on target, timing, and rate of AT supplementation are lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT supplementation in patients requiring veno-venous ECMO for respiratory failure.

Antithrombin supplementation during extracorporeal membrane oxygenation: study protocol for a pilot randomized clinical trial

Cipriani, Elisa;Sales, Gabriele;Fanelli, Vito;Brazzi, Luca;Consonni, Dario;
2019-01-01

Abstract

Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO). Acquired AT deficiency during ECMO is common, but formal recommendations on target, timing, and rate of AT supplementation are lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT supplementation in patients requiring veno-venous ECMO for respiratory failure.
2019
20
1
349
357
Panigada, Mauro; Spinelli, Elena; Cucino, Alberto; Cipriani, Elisa; De Falco, Stefano; Panarello, Giovanna; Occhipinti, Giovanna; Arcadipane, Antonio; Sales, Gabriele; Fanelli, Vito; Brazzi, Luca; Novembrino, Cristina; Consonni, Dario; Pesenti, Antonio; Grasselli, Giacomo
File in questo prodotto:
File Dimensione Formato  
2019 Trials Panigada.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 1.27 MB
Formato Adobe PDF
1.27 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1704364
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact